Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Amedisys

Amedisys Shows Rising Relative Price Performance; Still Shy Of Key Benchmark

A Relative Strength Rating upgrade for Amedisys shows improving technical performance. Will it continue?

Investors Business Daily

Amedisys Getting Closer To Key Technical Benchmark

Amedisys Getting Closer To Key Technical Benchmark

A Relative Strength Rating upgrade for Amedisys shows improving technical performance. Will it continue?

Investors Business Daily

Stocks With Rising Relative Strength: Amedisys

Stocks With Rising Relative Strength: Amedisys

A Relative Strength Rating upgrade for Amedisys shows improving technical performance. Will it continue?

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Stocks Showing Improved Relative Strength: Amedisys

A Relative Strength Rating upgrade for Amedisys shows improving technical performance. Will it continue?

Investors Business Daily

3 Stocks to Gain From Trump’s Family Caregiver Tax Credits

President Trump has spoken about implementing a family caregiver tax credit during his presidential campaign to ease the burden on caregivers, here's who gains.

Who Is Paulette Thompson: Quick Facts About Brian Thompson's Wife, How They Met and Their Kids

Paulette Thompson, wife of murdered UnitedHealthcare CEO, balances grief and supporting her family after revealing threats her husband faced over healthcare coverage.

International Business Times UK

UnitedHealthcare CEO Fatally Shot a Month After US DOJ Sues Parent Company's £2.59B Takeover of Amedisys

Brian Thompson was fatally shot in the chest outside the Hilton Hotel in midtown Manhattan, where UnitedHealth Group was about to begin its investor day. He was rushed to the Mount Sinai West Hospital but later succumbed to his injuries.

International Business Times UK

inkl

Read news from The Economist, FT, and more,
with one subscription

UnitedHealth's $33B Deal With Hospice Provider Blocked By DOJ

The United States Department of Justice is suing to block UnitedHealth Group's $3.3 billion acquisition of Amedisys, arguing that it would harm competition.

International Business Times

Justice Department sues to block UnitedHealth Group's $3.3 billion purchase of Amedisys

Justice Department sues to block UnitedHealth Group's $3.3 billion purchase of Amedisys

The Justice Department is suing to block UnitedHealth Group’s $3.3 billion purchase of Amedisys

The Independent UK

UnitedHealth buying home health care provider in $3.3B deal

UnitedHealth Group has struck a deal to acquire home health care provider Amedisys Inc. for $3.3 billion in an all-cash deal.

Tribune News Service

Benzinga's Top Ratings Upgrades, Downgrades For October 27, 2022

Benzinga's Top Ratings Upgrades, Downgrades For October 27, 2022

Benzinga's Top Ratings Upgrades, Downgrades For August 2, 2022

Benzinga's Top Ratings Upgrades, Downgrades For August 2, 2022

Stephens & Co. Maintains Equal-Weight Rating for Amedisys: Here's What You Need To Know

Stephens & Co. Maintains Equal-Weight Rating for Amedisys: Here's What You Need To Know

Stephens & Co. has decided to maintain its Equal-Weight rating of Amedisys (NASDAQ:AMED) and lower its price target from $155.00 to $125.00. Shares of Amedisys are trading down 12.59% over the last 24 hours, at $106.09 per share.

Analyst Ratings for Amedisys

Analyst Ratings for Amedisys

Analysts have provided the following ratings for Amedisys (NASDAQ:AMED) within the last quarter:

Get all your
news in one place.

100’s of premium titles.
One news app.

Analyst Ratings for Amedisys

Over the past 3 months, 5 analysts have published their opinion on Amedisys (NASDAQ:AMED) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

7 Analysts Have This to Say About Amedisys

Analysts have provided the following ratings for Amedisys (NASDAQ:AMED) within the last quarter:

Where Amedisys Stands With Analysts

Analysts have provided the following ratings for Amedisys (NASDAQ:AMED) within the last quarter:

Amedisys: Q4 Earnings Insights

Amedisys (NASDAQ:AMED) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Amedisys reported in-line EPS of $1.18 versus an estimate of $1.18.

Get all your
news in one place.

100’s of premium titles.
One news app.

People

138,998 stories

Paulette Thompson

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

the Justice Department

Investor Business Daily

UnitedHealthcare

UnitedHealth Group

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

302,804 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play